- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00624416
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lipomas are benign, non-cancerous fatty tumors that occur under the skin and make a bump that can be easily felt and often seen. The current treatment for lipomas is surgery. Isoproterenol, a medication used for the treatment of asthma and approved for injection under the skin, is known to cause fat cells to give up their fat. The fat cells become resistant to isoproterenol with repeated use. Prednisolone, a synthetic cortisone medication used to treat immune problems like allergy and approved for injection under the skin, keeps the fat cells from becoming resistant to isoproterenol. It is not known, if the fat cells in lipomas act like other fat cells or if the combination of isoproterenol and prednisolone injections would shrink lipomas without surgery. This study is designed to test this possibility.
Subjects will have a screening visit, 2 microdialysis visits a week apart, 20 treatment visits 5 days per week for 4 weeks, and up to 12 follow-up visits a year after treatment visits. During screening, subjects will have a history, physical exam, blood testing, electrocardiogram and a pregnancy testing if female with reproductive capacity. The first microdialysis visit will consist of placing two microdialysis catheters under the skin after the area is numbed. One microdialysis catheter will be in the lipoma and the other under the skin 2 inches away. The microdialysis catheter will connect to a pump, isoproterenol will be infused and the amount of fat breakdown measured. One week later prednisolone will be injected into the lipoma and under the skin 2 inches away. The microdialysis visit will be repeated 24 hours later.
Treatment will consist of injecting the lipoma 5 days a week with a mixture of isoproterenol and prednisolone in the Pennington clinic as a diabetic would inject insulin. Each week the blood pressure, pulse and lipoma will be measured and subjects will be asked how they feel. At the end of the treatment period the physical examination, blood test and electrocardiogram will be repeated.
The insertion of the microdialysis probes under the skin into the fat tissue could be uncomfortable, but numbing medication will be injected first to prevent this problem. At higher doses, isoproterenol could lower blood pressure and increase pulse rate. This should not happen at the doses used, but blood pressure and pulse will be monitored throughout the study. Prednisolone, at higher doses, could decrease the body's production of cortisone. This should not happen at the doses being used, but cortisone in the body will be measured during the trial. Blood tests involve the discomfort of a needle going through the skin of the arm, possible bruising and rarely fainting or infection. Trained technicians and sterile needles will minimize these risks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- You are a man or a woman between the ages of 18-60, inclusive.
- You have a body mass index (BMI) between 20 and less than 40 kg/m2. BMI is a number calculated from your height and weight.
- You have a lipoma (a benign fatty tumor) that is 1 inch or more in diameter under the skin of your abdomen or on another area of your body that is easily accessible to study (such as the thigh).
- You have not gained or lost more than 11 pounds in the last 3 months.
- Your exercise routine has been stable for the last 3 months or you are sedentary. Sedentary means you do less than 60 minutes of exercise per week.
Exclusion Criteria:
- You have a history of heart or blood vessel disease.
- Your blood pressure is above 140/90 mmHg.
- You have type 1 diabetes.
- You have a history of kidney or liver disease.
- You have thyroid disease that has not been treated.
- You are a smoker.
- You use a Beta-2 (B2) adrenergic stimulator (a type of drug used to treat asthma), a beta adrenergic blocker (a type of drug used to treat blood pressure) or glucocorticoid medications (a type of drug used to treat immune system disease).
- You have a problem with alcoholism or other substance abuse.
- You are pregnant or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Prednisolone and Isoproteronol Together
Beta-adrenergic agonists and corticosteroid
|
Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Average Percent Volume Reduction in the Lipoma.
Time Frame: Baseline and 4 weeks
|
Baseline and 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Number of Lipoma Increased in Volume.
Time Frame: After four weeks of treatment up to one year.
|
After four weeks of treatment up to one year.
|
The Number of Subjects Elected to Have the Lipoma Removed.
Time Frame: After four weeks up to one year.
|
After four weeks up to one year.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Leanne Redman, Ph.D., Pennington Biomedical Research Center
- Study Director: Frank Greenway, M.D., Pennington Biomedical Research Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Adipose Tissue
- Lipoma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Adrenergic Agonists
- Cardiotonic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Cortisone
- Isoproterenol
Other Study ID Numbers
- PBRC 27015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipoma
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustUnknownLipoma of Spinal CordUnited Kingdom
-
Universidade Metropolitana de SantosRecruiting
-
Kythera BiopharmaceuticalsCompleted
-
Zachary GerutAdvance Biofactures CorporationCompleted
-
Suez Canal UniversityCompleted
-
Gerut, Zachary, M.D.Advance Biofactures CorporationCompleted
-
Kythera BiopharmaceuticalsCompleted
-
Ruhr University of BochumCompletedSoft Tissue Sarcoma | Tumor | LipomaGermany
-
Yonsei UniversityCompletedVesico-Ureteral Reflux | Filum Terminale LipomaKorea, Republic of
-
University of MichiganAmryt PharmaEnrolling by invitationLipomatosis, Multiple SymmetricalUnited States
Clinical Trials on Prednisolone synthetic cortisone and Isoproterenol together
-
National Institute of Neurological Disorders and...Yale UniversityCompleted
-
Federico II UniversityRecruitingCongenital Adrenal HyperplasiaItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHead and Neck Carcinoma | Oropharyngeal Carcinoma | Cranial Nerve DisorderUnited States
-
Nordic Society for Pediatric Hematology and OncologyOulu University HospitalSuspendedAcute Lymphoblastic LeukemiaFinland, Denmark, Sweden, Iceland, Norway
-
Corcept TherapeuticsCompleted
-
Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI); Rocket Pharma LimitedActive, not recruiting
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 RearrangementsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnAcute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Childhood Hodgkin LymphomaUnited States, Canada, Puerto Rico
-
Children's Oncology GroupRecruitingRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditionsUnited States